Physician profile
Slater B Lowry
NPI 1619048204
$299.88
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $278 · 2022: $22.32.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $149.89 | 2019 | |
| Supernus Pharmaceuticals, INC. | $38.26 | 2019 | |
| Novo Nordisk INC | $24.25 | 2019 | |
| Janssen Pharmaceuticals, INC | $22.32 | 2022 | |
| Sanofi-Aventis U.S. LLC | $21.79 | 2019 | |
| Merck Sharp & Dohme LLC | $16.94 | 2019 | |
| Sunovion Pharmaceuticals INC. | $14.03 | 2019 | |
| Novartis Pharmaceuticals Corporation | $12.40 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Slater Lowry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.